<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215979</url>
  </required_header>
  <id_info>
    <org_study_id>05-20-2017</org_study_id>
    <nct_id>NCT03215979</nct_id>
  </id_info>
  <brief_title>Use of Platelet-enriched Plasma During Auricular Reconstruction</brief_title>
  <official_title>Use of Platelet-enriched Plasma to Improve the Percentage of Integration of the Cutaneous Graft During Second Stage of Auricular Reconstruction in Children Aged 8-12 Years; A Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Dr. Manuel Gea González</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Dr. Manuel Gea González</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study investigators are trying to determine the benefits of using platelet enriched
      plasma during the second stage of auricular reconstruction. The intervention will be blinded
      to the surgeon and the surgical team. The main outcome will be the evaluation of the
      integration rate of the skin full thickness graft used to coat the auricular frame.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">December 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Integration rate (in percentage) of the full thickness split graft sued during the second stage of auricular reconstruction.</measure>
    <time_frame>evaluation will be at day 10</time_frame>
    <description>Evaluation of the integration will be made on clinical basis, and evaluated by 3 experimented plastic surgeons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication</measure>
    <time_frame>evaluation will be at day 10</time_frame>
    <description>It refers to a deviation from the normal course of the pathology, 3 complications will be taken into account: infection, seroma and hematoma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Ear Cartilage</condition>
  <condition>Platelets</condition>
  <condition>Microtia-Anotia</condition>
  <arm_group>
    <arm_group_label>PEP-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, surgeon will be applying platelet enriched plasma(PEP) (5 ml) during the second stage procedure of auricular reconstruction. PEP will be infected in the temporal fascia used to cover the cartilage frame.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will be used as control. The surgeon will inject 0.9% saline solution (5ml) in a blinded basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet enriched plasma administration</intervention_name>
    <description>It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft</description>
    <arm_group_label>PEP-Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo Arm</intervention_name>
    <description>5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.</description>
    <arm_group_label>Placebo-Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Microtia Tanzer II-A

          -  patients aged 8-12 years

          -  Haemoglobin &gt; 10 gr/dL

          -  History of first stage of auricular reconstruction

        Exclusion Criteria:

          -  associated endocrinopathies

          -  desnutrition (&lt;2.5 gr/ dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital General &quot;Dr. Manuel Gea González&quot;</name>
      <address>
        <city>Mexico city</city>
        <zip>4800</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Raúl Carrillo-Córdova, M.D</last_name>
      <phone>01 55 4000 3000</phone>
      <phone_ext>1323</phone_ext>
      <email>dr.carrillo.plastica@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2017</study_first_submitted>
  <study_first_submitted_qc>July 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>February 20, 2018</last_update_submitted>
  <last_update_submitted_qc>February 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Dr. Manuel Gea González</investigator_affiliation>
    <investigator_full_name>Jorge Raúl Carrillo Córdova</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Microtia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

